Fluoride dental floss
Executive Summary
FDA should amend OTC Anticaries Drug Products TFM to disallow "the OTC marketing of sodium fluoride treated dental floss in the absence of clinical data showing superiority over comparable floss" without the cavity-fighting ingredient, Squibb unit Princeton Pharmaceuticals argues in a Nov. 14 petition. Firm maintains GRAS/E status of fluoride cannot be extended to a medical device (floss) on bioequivalency grounds as proposed by Johnson & Johnson in a July 1986 petition. J&J argued that dental floss can deliver fluoride with efficacy comparable to other methods of application ....
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: